ESMO 2018 | JAVELIN Renal 101: avelumab plus axitinib improve PFS for advanced renal cell cancer

The avidly awaited updates from key genitourinary cancer trials are finally here. From the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany, Robert Motzer, MD, of Memorial Sloan Kettering Cancer Center, New York, NY, provides an update on the JAVELIN Renal 101 study (NCT02684006), which investigated avelumab plus axitinib vs. sunitinib for as a first-line treatment for advanced renal cell cancer. Response rates were reported to be positive and progression-free survival data looking promising. There is currently uncertainty as to whether this will translate into similarly impressive survival signals and we will have to wait for the data to mature to find out.